The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

New in Community, Need your urgent Help

Forums General Melanoma Community New in Community, Need your urgent Help

  • Post
    FriendofMari
    Participant

      Hello everyone, Mari is the closest friend of mine, she was diagnosed choroidal malignang Melanoma in 2014 and had a surgery of enucleation in May 2014, since that everything seemed to be ok, buT unfortunately, in Januari 2016, were found 6 mets in liver, the biggest one is 1.5 sm. she is taking her treatment in Turkey, achebadim Clinic with Keytruda, she had injected the second one this week. She feels ok, but we have a very huge problem about money, Unfortunately our insurance does not cover fees, so we have to gather money every 3 weeks, for 7500 euro per injection. please help us about this problem, every $ matters.
      Here is a link of fundrising. please share among your friends.
      https://www.gofundme.com/allofusformari

      Also, we have a question, is here anyone who is NED after keytruda treatment? and how long is it lasting? thank you for your respond, sincerely, Maris friend Nino 🙂

    Viewing 5 reply threads
    • Replies
        FriendofMari
        Participant

          No answer ? okey….

          FriendofMari
          Participant

            No answer ? okey….

            FriendofMari
            Participant

              No answer ? okey….

              Bubbles
              Participant

                Dear Nino,

                I am sorry that you and your friend are facing financial difficulties to attain treatment as well as melanoma. As far as financing….sometimes if you contact the company (merck…in the case of Keytruda) you can attain some financial help. As far as Keytruda results…. pembolizumab/keytruda and nivolumab/opdivo are anti-PD1 immunotherapy products. They both have about a 40% response rate. Many here have had positive responses to that therapy. Some of us have managed to rid ourselves of any signs of disease, others gained a partial response, others have stable disease. You can search this forum for further discussion. In the US…the FDA approved both of these anti-PD1 products only in 2011…treatment is administered approximately 2 years or longer. So….we do not have any quantifiable duration of response numbers. I am sure more data in that area will be presented at ASCO (the American Society of Clinical Oncology's annual meeting in June) this year…and many eagerly await that information. There are many studies addressing anti-PD1, keytruda, and melanoma generally on my blog…use the search bubble if you are interested.  On a personal note….I am a melanoma patient….first diagnosed in 2003…Stage IV since 2010….NED since that point as well….having had nivo/Opdivo for 2 1/2 years. Hope that helps. Celeste

                 

                Bubbles
                Participant

                  Dear Nino,

                  I am sorry that you and your friend are facing financial difficulties to attain treatment as well as melanoma. As far as financing….sometimes if you contact the company (merck…in the case of Keytruda) you can attain some financial help. As far as Keytruda results…. pembolizumab/keytruda and nivolumab/opdivo are anti-PD1 immunotherapy products. They both have about a 40% response rate. Many here have had positive responses to that therapy. Some of us have managed to rid ourselves of any signs of disease, others gained a partial response, others have stable disease. You can search this forum for further discussion. In the US…the FDA approved both of these anti-PD1 products only in 2011…treatment is administered approximately 2 years or longer. So….we do not have any quantifiable duration of response numbers. I am sure more data in that area will be presented at ASCO (the American Society of Clinical Oncology's annual meeting in June) this year…and many eagerly await that information. There are many studies addressing anti-PD1, keytruda, and melanoma generally on my blog…use the search bubble if you are interested.  On a personal note….I am a melanoma patient….first diagnosed in 2003…Stage IV since 2010….NED since that point as well….having had nivo/Opdivo for 2 1/2 years. Hope that helps. Celeste

                   

                    FriendofMari
                    Participant

                      Thank you very much for your response, any information is very helpful and useful for us, I hope That everything will be ok with you and with my friend too, Ill read your blog, thank you again, we will try to contact to Merck, sincerely, Nino:)

                       

                      FriendofMari
                      Participant

                        Thank you very much for your response, any information is very helpful and useful for us, I hope That everything will be ok with you and with my friend too, Ill read your blog, thank you again, we will try to contact to Merck, sincerely, Nino:)

                         

                        FriendofMari
                        Participant

                          Thank you very much for your response, any information is very helpful and useful for us, I hope That everything will be ok with you and with my friend too, Ill read your blog, thank you again, we will try to contact to Merck, sincerely, Nino:)

                           

                        Bubbles
                        Participant

                          Dear Nino,

                          I am sorry that you and your friend are facing financial difficulties to attain treatment as well as melanoma. As far as financing….sometimes if you contact the company (merck…in the case of Keytruda) you can attain some financial help. As far as Keytruda results…. pembolizumab/keytruda and nivolumab/opdivo are anti-PD1 immunotherapy products. They both have about a 40% response rate. Many here have had positive responses to that therapy. Some of us have managed to rid ourselves of any signs of disease, others gained a partial response, others have stable disease. You can search this forum for further discussion. In the US…the FDA approved both of these anti-PD1 products only in 2011…treatment is administered approximately 2 years or longer. So….we do not have any quantifiable duration of response numbers. I am sure more data in that area will be presented at ASCO (the American Society of Clinical Oncology's annual meeting in June) this year…and many eagerly await that information. There are many studies addressing anti-PD1, keytruda, and melanoma generally on my blog…use the search bubble if you are interested.  On a personal note….I am a melanoma patient….first diagnosed in 2003…Stage IV since 2010….NED since that point as well….having had nivo/Opdivo for 2 1/2 years. Hope that helps. Celeste

                           

                      Viewing 5 reply threads
                      • You must be logged in to reply to this topic.
                      About the MRF Patient Forum

                      The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                      The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

                      Popular Topics